Arvinas击败了2025年Q3的收入估计数,尽管损失和收入不断下降,分析家预测2026年将继续遭受损失。 Arvinas beat earnings estimates in Q3 2025 despite a loss and declining revenue, with analysts projecting continued losses into 2026.

Arvinas报告了2025年Q3收入,每股亏损0.48美元,预期亏损75美元,收入4 190万美元,超过估计数1 254万美元,但比同年减少59.1%。 Arvinas reported Q3 2025 earnings with a loss of $0.48 per share, beating expectations of a $0.75 loss, and revenue of $41.9 million, exceeding estimates by $12.54 million, though down 59.1% year-over-year. 该公司正在开发基于PROTAC的蛋白质降解疗法,在股本和净差值方面有负回报。 The company, developing PROTAC-based protein-degrading therapies, has a negative return on equity and net margin. 分析员预测,损失持续到2026年,全年平均损失为每股3.81美元。 Analysts project continued losses into 2026, with a consensus full-year loss of $3.81 per share. 股票交易额为9.87美元,市场上限为7.2458亿美元,贝特为2.38美元,协商一致的“稳住”评级为16.34美元平均价格目标。 The stock, trading at $9.87, has a market cap of $724.58 million, a beta of 2.38, and a consensus “Hold” rating with a $16.34 average price target.